<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076503</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1513</org_study_id>
    <nct_id>NCT02076503</nct_id>
  </id_info>
  <brief_title>Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status</brief_title>
  <official_title>Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the most frequent cancer in Norwegian men. For optimal treatment, accurate
      staging of the disease at the time point of diagnosis is important. The objective of this
      study is to evaluate the diagnostic potential of a combined PET/MR examination for risk
      assessment and detection of lymph node metastases. The overall aim of the project is to
      improve the investigators ability to provide individually tailored treatment to prostate
      cancer patients.

      The study will include 32 men with high-risk prostate cancer, who are eligible for radical
      prostatectomy. Informed consent is a requirement for inclusion in the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and negative predictive value of 18FACBC PET/MR for detection of lymph node metastases</measure>
    <time_frame>7 days</time_frame>
    <description>Findings on 18FACBC PET/MR images will be compared to histopathology, which is considered the gold standard for evaluation of pelvic lymph node metastases</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>PET-MR 18F-FACBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET-MR 18f-FACBC</intervention_name>
    <arm_group_label>PET-MR 18F-FACBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>histology (gold standard)</intervention_name>
    <description>histopathological classification of co-located dissected lymph nodes</description>
    <arm_group_label>PET-MR 18F-FACBC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High-risk prostate cancer according to EAU guidelines (Gleason score ≥8 and/or PSA ≥20
             ng/ml and/or ≥ cT3a cancer)

          -  Eligibility for the surgical procedure (radical prostatectomy and bilateral pelvic
             lymph node resection)

        Exclusion Criteria:

          -  Previous treatment (for example TURP or hormone therapy)

          -  Contraindication for the PET/MR examination (including, but not limited to: pacemaker,
             aneurysm clips, reduced renal function, metal implants, claustrophobia)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Angelsen, prof</last_name>
    <role>Study Director</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept Urologic Surgery, St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Elschot M, Selnæs KM, Sandsmark E, Krüger-Stokke B, Størkersen Ø, Tessem MB, Moestue SA, Bertilsson H, Bathen TF. A PET/MRI study towards finding the optimal [(18)F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):695-703. doi: 10.1007/s00259-016-3562-7. Epub 2016 Nov 5.</citation>
    <PMID>27817158</PMID>
  </results_reference>
  <results_reference>
    <citation>Selnæs KM, Krüger-Stokke B, Elschot M, Willoch F, Størkersen Ø, Sandsmark E, Moestue SA, Tessem MB, Halvorsen D, Kjøbli E, Angelsen A, Langørgen S, Bertilsson H, Bathen TF. (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. Eur Radiol. 2018 Jan 2. doi: 10.1007/s00330-017-5213-1. [Epub ahead of print]</citation>
    <PMID>29294158</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasm Staging</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>1-amino-3-fluorocyclobutane-1-carboxylic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

